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ABSTRACT 
Objective: The objective of the present work was to develop an optimized dosage form for treating comorbidity in combination and evaluate it for 
its pharmacodynamic performance in male Wistar albino rats.  
Methods: Transdermal proniosomal gel for Combination of Glibenclamide (GLB) and Atenolol (ATN) was developed and optimized by Box Behnken 
design. This optimized combinational proniosomal gel (OCPG), which was selected by a point prediction method, was evaluated for its ex vivo, skin 
irritation studies and pharmacodynamic activities of both drugs in rats in comparison with its oral therapy.  
Results: The ex-vivo permeation behavior through different skins was studied and the findings were also confirmed by the values of the steady-
state flux (Jss
Conclusion: Overall, the results show that controlled release GLB and ATN proniosomes offer a useful and promising transdermal delivery system. 
Henceforth this may be an achievement in treating the diabetic hypertensive patient. 
). The OCPG observed an increase of more than twice in the cumulative amount of impregnated drugs compared to pure drug films. The 
study on skin irritation revealed the non-irritability of the developed OCPG applied. OCPG significantly showed sustained hypoglycemic activity in 
rats (p<0.001), when compared to orally treat animals up to 24 h. Systolic blood pressure (SBP) lowering effect of OCPG was found to be significant 
(p<0.02), when compared to orally treat rats up to 24 h. However, the reduction was slow and sustained in the case of OPCG where a significant 
response was observed in the performed studies. 
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INTRODUCTION 
Diabetes mellitus (DM) is a complex chronic disease that requires 
ongoing medical care and multi-factor strategies to reduce risk 
beyond glycemic control [1-3]. In DM, a constant increase in glucose 
levels can lead to chronic micro-and macro-vascular effects [4-7]. A 
patient with multiple comorbid conditions requires multiple 
medications to treat each condition, increasing side effects and 
treatment costs. Combined pharmacotherapies may provide additive 
benefits that target multiple disease processes [8]. Fixed-dose 
combination drugs (FDC’s) were originally developed to target only 
one disease. However, CFDCs can also target more than one 
disease/condition [9, 10]. However, no CDF has been developed for 
diabetes and its co-morbidities, like hypertension. 
Transdermal drug delivery systems offer a promising alternative to 
oral administration, particularly in preventing difficulties associated 
with this combination [11, 12]. This is particularly relevant for these 
products as these two classes of medications are administered at two 
different times (before and after the diet) when administered by the 
oral route [13]. Oral administration of GLB causes symptoms like 
headache or nausea, cold sweats, excessive hunger [14-16]. Atenolol 
(ATN) is widely used in the management of hypertension as 
monotherapy or in combination with other classes of antihypertensive 
agents [17]. The absorption of Atenolol upon oral administration in 
humans and most laboratory animal species is rapid but incomplete 
[18]. Thus the transdermal administration of GLB and ATN would have 
a better dosage form being that it increases bio-availability.  
Therefore, the combination of GLB and ATN through transdermal 
delivery can be a better therapeutic combination for effective 
control of diabetes and its coexisting cardiovascular complications 
(hypertension). The primary objective of this research was to assess 
the ex vivo and pharmacodynamic behavior of the optimized 
formulation of GLB and ATN obtained by designing Box Behnken as 
a proniosomal gel for transdermal administration. 
MATERIALS AND METHODS 
ATN and GLB were received as gift samples from Sun Pharma Ltd., 
Mumbai, India. Span 60 and cholesterol were purchased from SD 
Fine Chemicals, Mumbai, India. Phospholipid (Brand: Phospholipon 
90G) was a gift sample supplied by Phospholipid GmbH, 
Nattermannallee, Koln Germany. The other reagents and chemicals 
used were of analytical grade and were procured from Merck 
Limited, Mumbai, India. 
Preparation and optimization of proniosomes 
Coacervation-phase separation method was followed for the 
preparation of proniosomes, which was reported by Perrett and Vora 
[19, 20]. To assess the interaction impacts of surfactant, Phospholipid, 
and Cholesterol in the formulations; 3-factor, 3-level Box Behnken 
design was utilized. An absolute 17 test runs were produced by design 
expert Version 11 software [21]. The independent variables were 
surfactant (Span 60) (X1), Cholesterol (X2) and phospholipid 
(Phospholipon 90G) (X3) while Vesicle size (VZ) (Y1) entrapment 
efficiency of GLB and ATN (Y2 and Y3 respectively) were the 
dependent variables which are given in table 1. 
Ex vivo permeation study by using different skins 
Preparation of rabbit skin  
The preparation of skin was as per Xi et al. [22]. Male, white 
Newzeland Rabbits weighing 2.0-2.5 kg was obtained from the 
National center for laboratory animal sciences (NCLAS) after 
approval from the Institutional Animal Ethics Committee (IAEC 
No.: IAEC/ANCP/2018-19/02). All the animals used in the study 
were caged and maintained according to the guidelines of CPCSEA 
or principles established for the care and use of laboratory 
animals. After the rabbit was anesthetized with urethane (20 %, 
w/v), the skin was made hairless by applying hair removal cream 
(Veet® depilatory cream). The side of stratum corneum was 
extracted after the rabbit was sacrificed and the sub-dermal tissue 
was carefully removed. The side of the stratum corneum was 
cleaned with distilled water. The skin was washed with phosphate 
buffer saline (PBS), wrapped in aluminum foil and stored in a deep 
freezer at-20 °C till further use (used within 2 w of preparation) 
[23-25]. 
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Table 1: Independent and dependent variables used in box–behnken design for the development and optimization of proniosomal 
combination 
Variables Levels 
Independent variables -1 0 +1 
X1=Span 60 (mg) 450.00 675 900.00 
X2= Cholesterol (mg) 150.00 200 250.00 
X3= Phospholipid (mg) 900.00 1050 1200.00 
Dependent variables  Constraints   
Vesicle Size (Y1)  Minimum  
EE% of GLB (Y2)   Maximum 
EE% of ATN (Y3)   Maximum 
 
Preparation of rat skin 
Wistar albino male rats were obtained from the National center for 
laboratory animal sciences. All rats were kept under standard 
laboratory conditions in the 12-h light/dark cycle at 25 °C±2 °C 
provided by pellet diet (Lipton India Ltd., Bangalore) and water ad 
libitum. The animals were selected after superficial examination of 
the skin surface for abnormalities. The hair on the skin of Wistar 
albino male rat was clipped and subcutaneous tissues were 
removed, and dermis side was wiped with isopropyl alcohol to 
remove residual adhering fat. The skin was washed with PBS, 
wrapped in aluminum foil and stored in a deep freezer at-20 °C till 
further use (used within 2 w of preparation) [26]. 
Goat skin 
The hair on the skin of slaughtered goat was removed carefully and 
separated from the underlying cartilage with a scalpel. After 
separating the full-thickness skin, the fat adhering to the dermis side 
was removed using a scalpel and isopropyl alcohol [27]. 
Skin permeation studies 
The diffusion of GLB and ATN from the prepared gel, either contain 
pure drugs or OCPG, was carried out utilizing the same conditions 
for the method previously reported [28, 29]. A two-chamber 
horizontal Franz diffusion cell (volume of 12.5 ml and surface area 
of 3.14 cm2
Steady state flux (J 
) was utilized and the system was kept up at 37±0.5 °C. 
OCPG was spread on the stratum corneum side and two cells were 
clipped together. The skin was mounted over the diffusion cell in 
contact with the receptor compartment, which was cleaned before 
use. The receptor compartment was filled with diffusion medium 
(PBS, pH 7.4) and this receptor phase was continuously stirred at 
600 rpm with a Teflon-coated magnetic bar. Serial sampling was 
performed at specified time intervals (2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 
22, and 24 h) by removing the contents of the receptor compartment 
and replacing it with the fresh medium. The sample was examined 
utilizing the HPLC. From the obtained data, flux is calculated by 
using the below formula [30]. 
ss
Permeability Coefficient (K
) = Slope of the linear portion of the 
curve/Surface area of diffusion cell 
p) = flux/initial concentration of the drug 
in donor chamber = Jss/D
Enhancement Ratio (ER) = J
0  
ss  of proniosomes/Jss
Skin irritation studies 
 of control 
The study was performed by using healthy Male Newzeland Rabbits 
(2.5-3.0 kg) which were fed with food and water for 1 w to adapt to 
the environment before the study. For the skin irritation study, the 
rabbits were divided into three groups. Group 1 served as control. 
Group 2 received blank Proniosomal gel and Group 3 received OCPG 
on the previously shaven (24 h before the study) dorsal side of 
rabbits. Skin irritation study was performed as per the Draize 
scoring system (table 2) [31, 32]. The responses scored were noted 
approximately at 1, 2, 3and on the 7th day after the removal of the 
standard irritant and test formulations, rabbits were examined for 
signs of erythema and edema. The untreated skin of each rabbit was 
treated as a control for the respective test formulations [33, 34]. 
 
Table 2: Primary dermal irritation study of OCPG in rabbits: draize score evaluation criteria for skin reactions 
Value  Erythema Value  Edema formation 
0 No erythema 0 No edema 
1 Very slight erythema (barely perception), edges of area not well 
defined 
1 Very slight edema (barely perceptible. Edges of area 
not well defined) 
2 Slight erythema (pale red in color and edges definable) 2 Slight edema (edges of the area well defined by definite 
raising) 
3 Moderate to severe erythema (defined in color and area well defined) 3 Moderate edema (raised approximately 1 mm) 
4 Severe erythema (beet to crimson red) to slight scar formation 
(injuries in depth) 
4 Severe edema (raised more than 1 mm and extending 
beyond the area of exposure 
 
High-performance liquid chromatography (HPLC) of GLB and 
ATN 
The concentration of the combination of GLB and ATN in the 
samples was analyzed by using HPLC method (Water 2690 
composed of PDA-2996 detector) with BDS C18 250 × 2.1 mm, 1.6 µ 
columns. Data acquisition, recording, and chromatographic 
integration were performed by Empower 2 software. The mobile 
phase consisting of 0.01N potassium dihydrogen orthophosphate 
(pH 4.8) and acetonitrile taken in the ratio 55:45 with an injection 
volume of 1.0 ml in gradient mode with column oven temperature 
maintained at 30 °C. The flow rate was 1.0 ml/min and the detector 
was set at 235.0 nm. Method validation including recovery, 
specificity, and within-and between-day precision of HPLC was 
carried out, which was reported in our earlier work Anitha et al., 
[35]. 
Pharmacodynamic activity of OCPG 
Animal experiments were done as per the standards and guidelines 
set by the institutional animal ethical committee (IAEC No.: 
CBLRC/IAEC/13/01-2019). All wistar albino rats (150-180 g) were 
fed ad libitum and housed in light and dark cycle in an ambient 
temperature-controlled environment. They were placed into the rat 
holder for 5–6 d for a period of 10–20 min. By repeating the 
exercise, the animals taught to remain in the rat holder calmly and 
they became acquainted with the experimental conditions [36-39]. 
Antidiabetic activity of OCPG in rats 
Studies in normal rats 
Male Wistar albino rats (n=6) were fasted overnight only water was 
given. The hair in the neck region of the animals was removed using 
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a hair removal cream and OCPG was applied. The rats were left in 
individual cages, blood was withdrawn periodically from the orbital 
sinus at the interval of 0, 2, 4, 6, 8, 12, and 24 h and blood glucose 
levels were measured. GLB was administered orally as a suspension 
to another group of six rats after overnight fasting and blood glucose 
levels were estimated at intervals mentioned above. In both the 
cases each animal served as its own control and the hypoglycemic 
response was calculated by taking the difference in glucose levels at 
the 0 hour and subsequent hours. For the untreated group (n=6) of 
animals, after overnight fasting, the glucose levels were estimated by 
taking blood samples at 0, 6, 12 and 24 h [40]. 
Studies in diabetic rats 
The rats were fasted for 30 h and later rendered diabetic by an 
intraperitoneal injection of streptozocin (50 mg/kg body weight) in 
pH 4.5 citrate buffer. The blood glucose was measured after 24 h and 
rats with blood glucose levels>250 mg/dL were selected. The 
experimental protocol used in normal rats was followed in the 
assessment of hypoglycemic activity. The rats were divided into 3 
groups (n = 6). The rats were treated as follows, Group-I–oral 
administration of suspension of the marketed GLB, Group-II–GLB 
(single drug) Proniosomal gel (PNG), and Group-III–OCPG (ATN and 
GLB combination) was applied after application of Dermaroller on 
the previously shaven dorsal side of rats. An adhesive tape was 
rolled over the gel formulation to fix it securely to the site of 
application. The blood glucose level of each rat was measured at the 
interval of 0, 2, 4, 6, 8, 12, and 24 h using the One Touch glucometer 
[41]. 
Antihypertension activity of OCPG in rats 
Methyl prednisolone acetate (20 mg/kg/week) for 3 w was 
administered via the subcutaneous injection to 24 Wistar rats (n = 
6) for the induction of hypertension, and the SBP of these rats was 
measured by tail-cuff method (NIBP system IN125/R; AD Instrument 
Pvt. Ltd., Australia) and rats with the systolic pressure (SBP)>130 
mmHg were then selected for the experiment [42, 43]. Hypertension 
was successfully induced in all rats. The rats were treated as follows, 
Group-I–oral administration of suspension of the marketed ATN, 
Group-II–ATN (single drug) Proniosomal gel, and Group-III–OCPG 
(both drugs–ATN and GLB) was applied after application of 
Dermaroller on the previously shaven dorsal side of rats. An adhesive 
tape was rolled over the gel formulation to fix it securely to the site of 
application. SBP levels were measured just before and at 0, 2, 4, 6, 8, 
12, and 24h using the tail-cuff system [44, 45]. 
Data analysis 
Data were expressed as the mean±standard deviation of the mean, 
and statistical analysis was carried out by employing the one-way 
analysis of variance (ANOVA). A value of p<0.05 was considered to 
be statistically significant. 
RESULTS AND DISCUSSION 
In this study, various formulations were prepared containing GLB 
and ATN combination given in the design. The optimum formulation 
of Proniosomal gel was chosen dependent on the criteria of 
achieving the desirable value of vesicles size, entrapment efficiency 
of GLB and entrapment efficiency of ATN by applying numerical 
point prediction method. The OCPG formulation gives the 
experimentally observed values of vesicles size of 559 nm and 
entrapment efficiency of GLB is 97.037±1.43% and entrapment 
efficiency of ATN is 97.230±1.62%. These experimental values of 
vesicles size, entrapment efficiency of GLB and entrapment efficiency 
of ATN yielded by the OCPG Formulation were found in agreement 
with the predicted value of vesicles size (562±17.223 nm), entrapment 
efficiency of GLB (97.13±1.47%) and entrapment efficiency of ATN 
(97.42±1.85%) respectively created by design expert software, 
recommending that the optimized formulation was rational and 
reliable. The formulation composition with Surfactant (Span 60) 
(830.272 mg), Cholesterol (191.219 mg) and Phospholipid (900.00 
mg) were found to satisfy the essentials of an optimized combination 
proniosomal gel (OCPG) formulation. This formulation was successful 
in permitting the transdermal permeation of GLB and ATN. 
Ex vivo permeation study by using different skins 
Following the preparation of proniosomal gel loaded with OCPG; the 
ex-vivo permeation behavior through different skins was studied. 
The release profile from the transdermal gel loaded with OCPG was 
superior to normal patches. More than 2-fold increase in the 
cumulative amount of drug permeated was noticed from the OCPG 
when compared to pure drug films, which is evident from the values 
given in table 3. This finding was also confirmed by the values of the 
steady-state flux (Jss). It is obvious that OCPG formulation 
demonstrated the greatest flux over the rabbit skin and rat skin 
(0.221±0.04 mg/cm2/h and 0.583±0.02 mg/cm2/h, 0.229±0.06 
mg/cm2/h and 0.588±0.04 mg/cm2/h) of GLB and ATN respectively 
compared with goatskin (0.186±0.03 mg/cm2/h and 0.516±0.02 
mg/cm2/h), which is similar to findings of Imam et al. [46] and 
Alsarra et al. [47]. The permeability coefficient (Kp
 
) valuations for 
OCPG were 0.0221 cm/min and 0.0233 cm/min, 0.0229 cm/min and 
0.02352 cm/min of GLB and ATN respectively from rabbit and rat 
skin which is greater than goatskin (0.0186 cm/min and 0.0206 
cm/min). The permeation profiles of two drugs from different skins 
were shown in fig. 1 and 2. The permeation of GLB and ATN from the 
prepared gel either contains a pure drug or OCPG, was in favor of the 
Higuchi-diffusion model. According to the Korsmeyer-peppas model, 
the calculated n-values were greater than 0.45 but less than 0.89, 
indicating non-Fickian or anomalous release, which refers to a 
combination of both diffusion and erosion controlled-drug release 
mechanism. These results are in good agreement with previous 
work for a combination of drugs that have been loaded with a 
transdermal delivery system [45, 48]. 
 
Fig. 1: In vitro skin permeation profile of GLB from OCPG using different skins 
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Fig. 2: Ex vivo skin permeation profile of ATN from OCPG using different skins 
 
Table 3: Ex vivo permeation data of OCPG for different skin 
S. No. Ex vivo permeation Flux (mg/cm2 n-values /h) 
GLB ATN GLB ATN 
1 Rabbit Skin (OCPG) 0.221±0.04 0.583±0.02 0.608 0.650 
2 Rat Skin(OCPG) 0.229±0.06 0.588±0.04 0.575 0.642 
3 Goat Skin (OCPG) 0.186±0.03 0.516±0.02 0.595 0.493 
4 Control (Patches) 0.175±0.03 0.399±0.02 0.686 0.590 
Data for each response is presented in mean±SD (n=3) 
 
Skin irritation studies 
Based on the results, the skin irritation investigation depicted the 
non-irritancy of the developed OCPG applied. Results showed that 
the prepared OCPG was safe to be used for transdermal route. No 
obvious erythema, edema or inflammation was observed on the 
Male Newzeland Rabbit skin after one week of application of the 
selected formulation [49]. 
High-performance liquid chromatography (HPLC) of GLB and 
ATN 
An isocratic LC method, coupled with PDA detection, was developed 
for the simultaneous determination of ATN and GLB. Chromatogram 
A and chromatogram B represents the blank mobile phase and an 
average retention time of 2.322 min for GLB and 3.260 min for ATN, 
with no interfering peaks, respectively in fig. 3. According to ICH 
guidelines (International Council for Harmonisation), this method 
was validated. The validation characteristics were addressed in our 
earlier work Anitha et al., [35]. 
Pharmacodynamic activity 
Antidiabetic activity of OCPG in rats 
Studies in normal rats 
Hypoglycemic effect was significant in oral and OCPG applied group 
when compared with the untreated group (fig. 4). The untreated 
group of animals did not show any noticeable hypoglycemia. Oral 
GLB produced a decrease of 40.7±5.4% in blood glucose levels after 
2 h. In the case of OCPG, the maximum response was observed after 
8 h (30.4±5.4%) and thereafter remained stable up to 24 h 
(42.4±5.6%) and the hypoglycemic response was gradual. The blood 
glucose levels declined after 8 h and were only 5.5±4.3% after 24 h 
in an orally treated group, which is similar to findings mentioned in 
Sridevi et al., [39]. 
 
 
Fig. 3: HPLC chromatograms of mobile phase containing 10 µg/ml GLB and 25 µg/ml ATN (chromatogram B) 
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Fig. 4: Percent reduction in blood glucose levels after oral and OCPG administration in normal rats (n = 6, mean±SD) 
 
Studies in diabetic rats 
Results obtained from the diabetic rats after application of OCPG, 
GLB PNG and GLB oral administration are shown in (fig. 5). Blood 
Glucose levels obtained by from diabetic rats showed significant and 
almost similar hypoglycemic activity up to 24 h. The hypoglycemic 
effect produced by OCPG and GLB PNG in the rats is significantly less 
when compared to oral administration in the initial 4 h. The 
observed effect was found to be significant in case of OCPG treated 
animals (P<0.001), when compared to orally treat animals up to 24 
h. The GLB (oral) produced a decrease in blood glucose level up to 
90.12±9.23 mg/dL (P<0.05) for 4 h. In case of OCPG and GLB PNG, 
the hypoglycemic response was gradual. A maximum hypoglycemic 
response was observed after 8 h and remained stable up to 24 h (fig. 
5). The plasma insulin level was elevated to the maximum in oral, 
transdermal proniosomes (OCPG and GLB PNG) treated groups at 4 
h and 12 h, respectively as similar to the findings mentioned in 
Vijayan et al., [50].  
 
 
Fig. 5: Showing changes in blood glucose levels after oral administration of GLB suspension, GLB proniosomes and OCPG in streptozocin-
induced diabetic wistar albino rats. *P<0.001, significant difference in blood pressure with respect to oral treated group (n = 6, mean±SD) 
 
Antihypertension activity of OCPG in rats 
During antihypertensive study, hypertension was induced in all rats 
in a successful manner after subcutaneous injection of methyl 
prednisolone acetate (20 mg/kg/week for 3 w). There is a 
significant difference in SBP values in pre-and post-treatment with 
methylprednisolone acetate in Wistar albino rats. The changes in 
systolic blood pressure (SBP) (mm Hg) after oral administration of 
marketed ATN, ATN PNG and OCPG in methylprednisolone acetate-
induced hypertensive wistar rats are presented in fig. 6. An early 
drug action was observed in Group 1 after oral administration of 
ATN; hypertension was significantly reduced to normal value with 
the maximum reduction in SBP (110.67±3.33 mm Hg) observed at 2 
h. After 6 h of oral administration, SBP progressively started to rise 
and reached up to 125.50±4.62 mm Hg at 12 h and reached 
140.83±3.12 mm Hg at 24 h (P<0.05) after oral administration. The 
observed effect was found to be significant in the case of OCPG 
treated rats (P<0.02), when compared to orally treat rats up to 24 h. 
On the other hand, ATN PNG and OCPG steadily decrease the SBP 
and maximum action of the drug observed after 4 h after 
transdermal application (SPB 115.50±4.26 mm Hg) in hypertensive 
rats, which is similar to findings in Abdul Ahad et al., [51]. The SBP 
lowering effect of proniosomal gel formulation was sustained and 
maintained up to the complete duration of study i.e. 24 h. It is 
concluded that the developed OCPG formulation released the drug 
gradually and efficaciously controlled the SBP in rats up to 24 h. 
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Fig. 6: Showing changes in systolic blood pressure (mm Hg) after oral administration of ATN suspension, ATN proniosomes and OCPG in 
methyl prednisolone acetate-induced hypertensive wistar albino rats. *P<0.02, significant difference in blood pressure with respect to 
oral treated group (n = 6, mean±SD) 
 
CONCLUSION 
Transdermal route not only effectively maintained normoglycemic 
levels in contrast to the oral group but also an effective approach for 
treating its Comorbidities i.e., hypertension in combination, which 
produced remarkable hypoglycemia and controlled SBP, which is an 
indication that a similar episode might be prevented in diabetic 
hypertensive patients. This study showed that proniosomal 
transdermal administration of a combination of GLB and ATN 
showed better control of high blood sugar and hypertension, in 
addition to reversing complications of diabetes mellitus more 
efficiently than oral administration in rats. However, ex vivo 
assessment, pharmacokinetics and pharmacodynamics of these 
systems in human volunteers is required to confirm these results. 
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